Ann: FY17 Full Year Results Announcement, page-13

from the report:

 Positive net working capital and cash balances totalling $17,284,125
 New product linessuch as CardioCel® Neo, VascuCel® and CardioCel® 3D that are at varying stages of introduction in our existing markets  
 New markets for the Groups ADAPT® products including India, Australia, Philippines, Taiwan, Vietnam, Spain, Hungary, Baltics and Mexico  
 New partnerships and alliances    Contract wins for the infusion business
 Monitoring, management and containment of discretionary costs, including R&D costs, and capital expenditures 25 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2017 1. SIGNIFICANT ACCOUNTING POLICIES (continued)
 The Group’s cash flow forecaststhat incorporatessome but not all of the above factors, thus providing some upside sensitivity, indicated that the Group will be in a positive cash position during the period of twelve months from the date of approval of this report
 In addition, the Directors believe that the Group has the capacity to raise debt finance should it be required in the future   End Quote

So the last line sums it up for me, no CR, they will use available cash and raise DEBT finance if need be as a bridge until last quarter of 2018 where the company will become fully profitable.

DYOR